Provided are compositions and methods for the identification and treatment of cancers exhibiting reduced MRE11/RAD50/NBS1 (MRN) complex formation and/or functionality as well as methods for the identification and use of cytotoxic agents, including clastogenic agents, for the treatment of cancers exhibiting reduced MRN complex formation and/or functionality. Also provided are methods for detecting and treating cancers, in particular breast cancers, such as hormone-negative breast cancers (HNBCs) and triple- negative breast cancers (TNBCs), colorectal cancers, urothelial cancers, and other cancers that exhibit reduced MRN complex formation and/or functionality and are correspondingly sensitive to growth and/or survival inhibition by one or more cytotoxic agents.
展开▼